NO20092231L - Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav - Google Patents
Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse deravInfo
- Publication number
- NO20092231L NO20092231L NO20092231A NO20092231A NO20092231L NO 20092231 L NO20092231 L NO 20092231L NO 20092231 A NO20092231 A NO 20092231A NO 20092231 A NO20092231 A NO 20092231A NO 20092231 L NO20092231 L NO 20092231L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- compounds
- disease
- nervous system
- central nervous
- Prior art date
Links
- -1 Arylvinyl azacycloalkane compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019430 Motor disease Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 abstract 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Nye vinylazacykloalkan-forbindelser med formel (I) er beskrevet. Forbindelsene er ligander for forskjellige nAChR. Forbindelsene og deres farmasøytisk akseptable salter kan anvendes for å fremstille farmasøytiske preparater og/eller medikamenter ment for å forhindre eller behandle lidelser forbundet med dysfunksjon av nAChR, spesielt innen sentralnervesystemet eller mave-tarm-systemet.Eksempler på typer av lidelser som kan behandles omfatter neurodegenerative lidelser, omfattende sentralnervesystem-lidelser så som Alzheimer's sykdom, kognitive lidelser, motoriske lidelser så som Parkinson's sykdom, medikament-avhengighet, adferdsmessige lidelser og infiammatoriske lidelser i mave-tarm-systemet. Forbindelsene kan også tjene som smertestillende midler ved behandling av akutt, kronisk eller tilbakevendende smerte.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/379,868 US7098331B2 (en) | 2003-03-05 | 2003-03-05 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| PCT/US2004/006530 WO2004078752A1 (en) | 2003-03-05 | 2004-03-04 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092231L true NO20092231L (no) | 2005-10-03 |
Family
ID=32926772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054120A NO331920B1 (no) | 2003-03-05 | 2005-09-05 | Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling |
| NO20091888A NO332293B1 (no) | 2003-03-05 | 2009-05-14 | Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom |
| NO20092231A NO20092231L (no) | 2003-03-05 | 2009-06-09 | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054120A NO331920B1 (no) | 2003-03-05 | 2005-09-05 | Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling |
| NO20091888A NO332293B1 (no) | 2003-03-05 | 2009-05-14 | Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US7098331B2 (no) |
| EP (3) | EP1601670B1 (no) |
| JP (3) | JP4663627B2 (no) |
| KR (4) | KR101185541B1 (no) |
| CN (3) | CN100526308C (no) |
| AR (3) | AR043469A1 (no) |
| AT (3) | ATE496046T1 (no) |
| AU (3) | AU2004217903B2 (no) |
| BR (1) | BRPI0409576A (no) |
| CA (1) | CA2516514C (no) |
| CL (1) | CL2004000452A1 (no) |
| CY (2) | CY1110391T1 (no) |
| DE (2) | DE602004013553D1 (no) |
| DK (2) | DK1601670T3 (no) |
| EA (3) | EA010870B1 (no) |
| ES (3) | ES2385941T3 (no) |
| GT (1) | GT200400033A (no) |
| IL (3) | IL170155A (no) |
| JO (1) | JO2488B1 (no) |
| MX (1) | MXPA05009386A (no) |
| NO (3) | NO331920B1 (no) |
| NZ (1) | NZ541795A (no) |
| PA (1) | PA8597201A1 (no) |
| PE (1) | PE20040930A1 (no) |
| PL (5) | PL394600A1 (no) |
| PT (2) | PT1601670E (no) |
| SI (2) | SI1601670T1 (no) |
| TW (3) | TW200927746A (no) |
| UY (1) | UY28218A1 (no) |
| WO (1) | WO2004078752A1 (no) |
| ZA (1) | ZA200506790B (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| US20110098312A1 (en) * | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| TW201024283A (en) * | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| PL3279195T3 (pl) * | 2008-12-01 | 2020-12-14 | Oyster Point Pharma, Inc. | Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| CN102802630A (zh) * | 2009-06-17 | 2012-11-28 | 塔加西普特公司 | 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍 |
| PH12012501068A1 (en) | 2009-12-07 | 2013-02-04 | Targacept Inc | 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands |
| WO2011112428A2 (en) * | 2010-03-11 | 2011-09-15 | Targacept, Inc. | Arylvinylazacycloalkane compounds for constipation |
| US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US20140081714A1 (en) * | 2012-09-19 | 2014-03-20 | Salesforce.Com, Inc. | Systems and methods of rewarding users in an on-demand system |
| US20140278929A1 (en) * | 2013-03-15 | 2014-09-18 | Yahoo! Inc. | System and method identifying opportunities for advertising entities based on user goal achievement |
| CN109310692B (zh) | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| KR101848601B1 (ko) * | 2016-07-27 | 2018-04-12 | 송기봉 | 일회용 위생 티슈 |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| TW202019417A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合 |
| ES3039903T3 (en) | 2020-04-28 | 2025-10-27 | Oyster Point Pharma Inc | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6437138B1 (en) * | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| ATE491689T1 (de) | 1997-10-27 | 2011-01-15 | Neurosearch As | Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren |
| JP2003501416A (ja) | 1999-06-07 | 2003-01-14 | ターガセプト，インコーポレイテッド | 医薬組成物およびその使用法 |
| JP2003529547A (ja) | 1999-09-14 | 2003-10-07 | アボット・ラボラトリーズ | 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物 |
| JP2003513054A (ja) | 1999-11-01 | 2003-04-08 | ターガセプト，インコーポレイテッド | アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用 |
| US6624167B1 (en) * | 2000-08-04 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| AU2002322562A1 (en) | 2001-07-19 | 2003-03-03 | Medical College Of Georgia Research Institute | Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders |
| US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
-
2003
- 2003-03-05 US US10/379,868 patent/US7098331B2/en not_active Expired - Lifetime
-
2004
- 2004-02-10 TW TW098105932A patent/TW200927746A/zh unknown
- 2004-02-10 TW TW093103017A patent/TWI339662B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105931A patent/TWI377204B/zh not_active IP Right Cessation
- 2004-03-02 PE PE2004000228A patent/PE20040930A1/es not_active Application Discontinuation
- 2004-03-04 EA EA200501425A patent/EA010870B1/ru active IP Right Revival
- 2004-03-04 BR BRPI0409576-6A patent/BRPI0409576A/pt not_active IP Right Cessation
- 2004-03-04 EA EA200900706A patent/EA019240B1/ru not_active IP Right Cessation
- 2004-03-04 UY UY28218A patent/UY28218A1/es not_active Application Discontinuation
- 2004-03-04 AT AT09075124T patent/ATE496046T1/de active
- 2004-03-04 KR KR1020057016343A patent/KR101185541B1/ko not_active Expired - Fee Related
- 2004-03-04 AR ARP040100690A patent/AR043469A1/es not_active Application Discontinuation
- 2004-03-04 KR KR1020127001576A patent/KR20120014236A/ko not_active Ceased
- 2004-03-04 CN CNB2004800060242A patent/CN100526308C/zh not_active Expired - Lifetime
- 2004-03-04 JO JO200422A patent/JO2488B1/en active
- 2004-03-04 EP EP04717398A patent/EP1601670B1/en not_active Expired - Lifetime
- 2004-03-04 DK DK04717398T patent/DK1601670T3/da active
- 2004-03-04 KR KR1020097002098A patent/KR101018083B1/ko not_active Expired - Fee Related
- 2004-03-04 AT AT08075106T patent/ATE517893T1/de not_active IP Right Cessation
- 2004-03-04 ES ES09075124T patent/ES2385941T3/es not_active Expired - Lifetime
- 2004-03-04 PL PL394600A patent/PL394600A1/pl unknown
- 2004-03-04 AT AT04717398T patent/ATE394394T1/de active
- 2004-03-04 CA CA2516514A patent/CA2516514C/en not_active Expired - Lifetime
- 2004-03-04 PL PL394604A patent/PL215059B1/pl unknown
- 2004-03-04 PA PA20048597201A patent/PA8597201A1/es unknown
- 2004-03-04 EP EP09075124A patent/EP2085395B1/en not_active Expired - Lifetime
- 2004-03-04 AU AU2004217903A patent/AU2004217903B2/en not_active Ceased
- 2004-03-04 EA EA200801764A patent/EA014714B1/ru not_active IP Right Cessation
- 2004-03-04 PL PL04717398T patent/PL1601670T3/pl unknown
- 2004-03-04 SI SI200430775T patent/SI1601670T1/sl unknown
- 2004-03-04 ES ES08075106T patent/ES2389106T3/es not_active Expired - Lifetime
- 2004-03-04 DK DK09075124.9T patent/DK2085395T3/da active
- 2004-03-04 PL PL09075124T patent/PL2085395T3/pl unknown
- 2004-03-04 EP EP08075106A patent/EP1947100B1/en not_active Expired - Lifetime
- 2004-03-04 SI SI200431638T patent/SI2085395T1/sl unknown
- 2004-03-04 NZ NZ541795A patent/NZ541795A/en not_active IP Right Cessation
- 2004-03-04 ES ES04717398T patent/ES2309507T3/es not_active Expired - Lifetime
- 2004-03-04 CN CN2009100048828A patent/CN101550132B/zh not_active Expired - Fee Related
- 2004-03-04 JP JP2006509059A patent/JP4663627B2/ja not_active Expired - Fee Related
- 2004-03-04 KR KR1020097002099A patent/KR100953150B1/ko not_active Expired - Fee Related
- 2004-03-04 PL PL378415A patent/PL216979B1/pl unknown
- 2004-03-04 DE DE602004013553T patent/DE602004013553D1/de not_active Expired - Lifetime
- 2004-03-04 DE DE602004031165T patent/DE602004031165D1/de not_active Expired - Lifetime
- 2004-03-04 GT GT200400033A patent/GT200400033A/es unknown
- 2004-03-04 CN CNA2008100917335A patent/CN101255155A/zh active Pending
- 2004-03-04 MX MXPA05009386A patent/MXPA05009386A/es active IP Right Grant
- 2004-03-04 PT PT04717398T patent/PT1601670E/pt unknown
- 2004-03-04 WO PCT/US2004/006530 patent/WO2004078752A1/en not_active Ceased
- 2004-03-04 PT PT09075124T patent/PT2085395E/pt unknown
- 2004-03-08 CL CL200400452A patent/CL2004000452A1/es unknown
-
2005
- 2005-08-08 IL IL170155A patent/IL170155A/en active IP Right Grant
- 2005-08-17 US US11/206,243 patent/US20060094732A1/en not_active Abandoned
- 2005-08-24 ZA ZA200506790A patent/ZA200506790B/xx unknown
- 2005-09-05 NO NO20054120A patent/NO331920B1/no not_active IP Right Cessation
-
2008
- 2008-08-06 CY CY20081100831T patent/CY1110391T1/el unknown
- 2008-08-07 US US12/187,584 patent/US7714001B2/en not_active Expired - Lifetime
- 2008-12-17 AU AU2008258188A patent/AU2008258188B2/en not_active Ceased
- 2008-12-17 AU AU2008258187A patent/AU2008258187B2/en not_active Ceased
-
2009
- 2009-01-05 US US12/348,605 patent/US8063068B2/en not_active Expired - Lifetime
- 2009-02-05 AR ARP090100389A patent/AR070570A2/es not_active Application Discontinuation
- 2009-02-05 AR ARP090100388A patent/AR070569A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197889A patent/IL197889A/en active IP Right Grant
- 2009-04-05 IL IL197890A patent/IL197890A/en active IP Right Grant
- 2009-05-14 NO NO20091888A patent/NO332293B1/no not_active IP Right Cessation
- 2009-06-09 NO NO20092231A patent/NO20092231L/no unknown
- 2009-07-31 JP JP2009178897A patent/JP5537085B2/ja not_active Expired - Lifetime
- 2009-07-31 JP JP2009178896A patent/JP5537084B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,106 patent/US8067443B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 US US13/033,719 patent/US8633222B2/en not_active Expired - Fee Related
- 2011-04-05 CY CY20111100351T patent/CY1111615T1/el unknown
-
2013
- 2013-12-17 US US14/108,918 patent/US20140107164A1/en not_active Abandoned
-
2015
- 2015-02-24 US US14/629,517 patent/US20150164894A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| PL398445A1 (pl) | Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych | |
| WO2001060826A3 (en) | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| NO20085398L (no) | Nye 1,4-diazabisyklo[3.2 2]nonyloksadiazolylderivater og deres medisinske anvendelse | |
| WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| CA2581025A1 (en) | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | |
| CA2417106A1 (en) | Piperazine derivatives | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| TW200635903A (en) | Therapeutic agents | |
| WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
| TW200633986A (en) | Therapeutic agents | |
| BR0314183A (pt) | Derivados de 1,4-diazabicicloalcano, quaisquer de seus enanciÈmeros ou qualquer mistura de seus enaciÈmeros, ou um seu sal de adição farmaceuticamente aceitável ou um seu n-óxido, composição farmacêutica, uso do dito composto, de qualquer um de seus enanciÈmeros ou de qualquer mistura de seus enanciÈmeros, ou de um seu sal de adição farmaceuticamente aceitável, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo animal vivo | |
| ATE465735T1 (de) | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen | |
| UA88634C2 (en) | Quaternized quinuclidine esters | |
| EP1972342A4 (en) | PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA | |
| TW200510331A (en) | Heteroaryl-substituted imidazole derivatives | |
| MXPA06000193A (es) | Derivados de imidazol iii. | |
| WO2024249559A3 (en) | Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction | |
| JP2009510158A (ja) | 毒物依存症の治療におけるネボグラミンの使用 | |
| WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
| WO2020106454A3 (en) | Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction | |
| WO2006042389B1 (en) | Hydroalcoholic extract of erythrina mulungu, pharmaceutical compositions and processes for producing these substances |